重组人卵磷脂胆固醇酰基转移酶在急性ST段抬高型心肌梗死中的随机安慰剂对照2b期研究:REAL-TIMI 63B结果
REAL-TIMI 63B为多国、安慰剂对照、随机2b期试验,纳入症状发作6小时内且拟行经皮冠状动脉介入的ST段抬高型心肌梗死患者593例,按2:1随机接受MEDI6012(2或6剂方案)或安慰剂并随访12周。主要终点为10-12周心脏磁共振评估的梗死面积占左心室质量百分比,在介入前TIMI血流0-1级且至少接受2剂MEDI6012的患者中分析;结果显示治疗组与安慰剂组梗死面积无显著差异(9.71% vs 10.48%,单侧P=0.79),非钙化斑块体积亦无差异(几何均值比0.96,95%CI NA-1.10,单侧P=0.30)。MEDI6012耐受良好,治疗中出现严重不良事件无显著差异。
要点
- MEDI6012未显著减少12周心脏磁共振评估的梗死面积。
- 非钙化斑块体积变化在两组间无显著差异。
- MEDI6012耐受良好,未增加总体严重不良事件。
核心结论
- 急性ST段抬高型心肌梗死患者接受MEDI6012治疗未显著降低12周梗死面积或非钙化斑块体积。
- MEDI6012耐受良好,未增加总体严重不良事件。
研究设计与样本
- REAL-TIMI 63B为2b期多国、安慰剂对照、随机试验,共随机分配593例患者。
- 纳入症状发作6小时内且拟行经皮冠状动脉介入的ST段抬高型心肌梗死患者,按2:1随机接受MEDI6012(2或6剂方案)或安慰剂,随访12周。
- 主要终点为10-12周心脏磁共振评估的梗死面积占左心室质量百分比,主要分析人群为介入前TIMI血流0-1级且至少接受2剂MEDI6012的患者。
- 次要终点为基线至10-12周冠状动脉CT血管造影非钙化斑块体积变化,主要分析人群为接受全部6剂MEDI6012的患者。
主要发现
- 患者中位年龄62岁,男性占77.9%,95.8%为他汀初治。
- 症状发作至随机化中位时间146分钟(IQR 103-221),住院至随机化中位时间12.7分钟(IQR 6.6-24.0),首剂药物在介入前中位8分钟(IQR 3-13)给药。
- 索引心肌梗死前壁占69.6%,TIMI血流0-1级占65.1%。
- 12周时梗死面积两组无差异:MEDI6012组9.71%(IQR 4.79-16.38),安慰剂组10.48%(IQR 4.92-16.61),单侧P=0.79。
- 非钙化斑块体积无差异:几何均值比0.96(95%CI NA-1.10),单侧P=0.30。
临床怎么用
- 目前证据不支持在急性ST段抬高型心肌梗死患者中使用MEDI6012以缩小梗死面积或改善斑块体积。
- MEDI6012在该人群中耐受良好,但需进一步研究确认其临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-density lipoprotein plays a key role in reverse cholesterol transport. In addition, high-density lipoprotein particles may be cardioprotective and reduce infarct size in the setting of myocardial injury. Lecithin-cholesterol acyltransferase is a rate-limiting enzyme in reverse cholesterol transport. MEDI6012 is a recombinant human lecithin-cholesterol acyltransferase that increases high-density lipoprotein cholesterol. Administration of lecithin-cholesterol acyltransferase has the potential to reduce infarct size and regress coronary plaque in acute ST-segment-elevation myocardial infarction. METHODS: REAL-TIMI 63B (A Randomized, Placebo‑controlled Phase 2b Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction) was a phase 2B multinational, placebo-controlled, randomized trial. Patients with ST-segment-elevation myocardial infarction within 6 hours of symptom onset and planned for percutaneous intervention were randomly assigned 2:1 to MEDI6012 (2- or 6-dose regimen) or placebo and followed for 12 weeks. The primary outcome was infarct size as a percentage of left ventricular mass by cardiac MRI at 10 to 12 weeks, with the primary analysis in patients with TIMI Flow Grade 0 to 1 before percutaneous intervention who received at least 2 doses of MEDI6012. The secondary outcome was change in noncalcified plaque volume on coronary computed tomographic angiography from baseline to 10 to 12 weeks with the primary analysis in patients who received all 6 doses of MEDI6012. RESULTS: A total of 593 patients were randomly assigned. Patients were a median of 62 years old, 77.9% male, and 95.8% statin naive. Median time from symptom onset to randomization was 146 (interquartile range [IQR], 103-221) minutes and from hospitalization to randomization was 12.7 (IQR, 6.6-24.0) minutes, and the first dose of drug was administered a median of 8 (IQR, 3-13) minutes before percutaneous intervention. The index myocardial infarction was anterior in 69.6% and TIMI Flow Grade 0 to 1 in 65.1% of patients. At 12 weeks, infarct size did not differ between treatment groups (MEDI6012: 9.71%, IQR 4.79-16.38; placebo: 10.48%, [IQR, 4.92-16.61], 1-sided P=0.79. There was also no difference in noncalcified plaque volume (geometric mean ratio, 0.96 [95% CI, NA-1.10], 1-sided P=0.30). There was no significant difference in treatment emergent serious adverse events. CONCLUSIONS: Administration of MEDI6012 in patients with acute ST-segment-elevation myocardial infarction did not result in a significant reduction in infarct size or noncalcified plaque volume at 12 weeks. MEDI6012 was well tolerated with no excess in overall serious adverse events. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03578809.
引用
- Bonaca, Morrow, Bergmark, et al. Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B. Circulation. 2022. PMID: 36039762. doi:10.1161/CIRCULATIONAHA.122.059325
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。